The Antibiotic Susceptibility of Escherichia coli from Community-Acquired Uncomplicated Urinary Tract Infection: A Focused on Fosfomycin
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: To assess the antibiotic susceptibility of Escherichia coli from commu-nity-acquired uncomplicated urinary tract infection (UTI).Materials and Methods: Between August and December of 2015, confirmed cases of E. coli as a pathogen of community-acquired uncomplicated UTI were collected and assessed for antibiotic susceptibility in 10 designated hospitals. Additional fosfomycin susceptibility test was performed by a central laboratory using the disk diffusion method.Results: A total of 347 E. coli isolates were collected from urine samples of community-acquired uncomplicated UTIs patients. The susceptibility rates of antibiotics were as follows: amikacin 100.0% (347), imipenem 100.0% (347), ciprofloxacin 57.1% (198), cefotaxime 74.9% (260), ampicillin 30.0% (104), trimethoprim/sulfamethoxazole 66.9% (232), and fosfomycin 98.0% (340). All fosfomycin-resistant E. coli isolates were extended-spectrum -lactamase (ESBL)-producing. In 85 cases of ESBL-producing E. coli, the fosfomycin susceptibility rate was 91.8% (78/85).Conclusions: Fosfomycin may be a useful option for the treatment of community-acquired uncomplicated UTIs. Further studies evaluating the role of fosfomycin in the treatment of UTIs and its clinical efficacy are necessary.
Abstract
Purpose: To assess the antibiotic susceptibility of Escherichia coli from commu-nity-acquired uncomplicated urinary tract infection (UTI).Materials and Methods: Between August and December of 2015, confirmed cases of E. coli as a pathogen of community-acquired uncomplicated UTI were collected and assessed for antibiotic susceptibility in 10 designated hospitals. Additional fosfomycin susceptibility test was performed by a central laboratory using the disk diffusion method.Results: A total of 347 E. coli isolates were collected from urine samples of community-acquired uncomplicated UTIs patients. The susceptibility rates of antibiotics were as follows: amikacin 100.0% (347), imipenem 100.0% (347), ciprofloxacin 57.1% (198), cefotaxime 74.9% (260), ampicillin 30.0% (104), trimethoprim/sulfamethoxazole 66.9% (232), and fosfomycin 98.0% (340). All fosfomycin-resistant E. coli isolates were extended-spectrum -lactamase (ESBL)-producing. In 85 cases of ESBL-producing E. coli, the fosfomycin susceptibility rate was 91.8% (78/85).Conclusions: Fosfomycin may be a useful option for the treatment of community-acquired uncomplicated UTIs. Further studies evaluating the role of fosfomycin in the treatment of UTIs and its clinical efficacy are necessary.
참고문헌 (19)
- Hooton TM, "Clinical practice. Uncomplicated urinary tract infection", N Engl J Med, 366, pp.1028~1037 (2012)
- Jorgensen JH, "Antimicrobial susceptibility testing: a review of general principles and contemporary practices", Clin Infect Dis, 49, pp.1749~1755 (2009)
- Kim HY, "Microbiological characteristics of unresolved acute uncomplicated cystitis", Microb Drug Resist, 22, pp.387~391 (2016)
- Miller LG, "Treatment of uncomplicated urinary tract infections in an era of increasing antimicrobial resistance", Mayo Clin Proc, 79, pp.1048~1053 (2004)
- Dhariwal AK, "Colistin: re-emergence of the ‘forgotten' antimicrobial agent", J Postgrad Med, 59, pp.208~215 (2013)
- Popovic M, "Fosfomycin: an old, new friend?", Eur J Clin Microbiol Infect Dis, 29, pp.127~142 (2010)
- Saiprasad PV, "Exploring the hidden potential of fosfomycin for the fight against severe Gram-negative infections", Indian J Med Microbiol, 34, pp.416~420 (2016)
- Raz R, "Fosfomycin: an old--new antibiotic", Clin Microbiol Infect, 18, pp.4~7 (2012)
- Thaden JT, "Role of newer and re-emerging older agents in the treatment of infections caused by carbapenem-resistant Enterobacteriaceae", Virulence, 8, pp.403~416 (2017)
- Naber KG, "Fosfomycin trometamol versus ofloxacin", co-trimoxazole as single dose therapy of acute uncomplicated urinary tract infection in females: a multicentre study, 1990, pp.18(Suppl 2), S70~S76
- Karageorgopoulos DE, "Fosfomycin: evaluation of the published evidence on the emergence of antimicrobial resistance in Gram-negative pathogens", J Antimicrob Chemother, 67, pp.255~268 (2012)
- Oteo J, "CTX-M-15-producing urinary Escherichia coli O25b-ST131-phylogroup B2 has acquired resistance to fosfomycin", J Antimicrob Chemother, 64, pp.712~717 (2009)
- Lorente Garin JA, "Antibiotic resistance transformation in community-acquired urinary infections", Rev Clin Esp, 205, pp.259~264 (2005)
- Schito GC, "Why fosfomycin trometamol as first line therapy for uncomplicated UTI?", Int J Antimicrob Agents, 22(Suppl 2), pp.79~83 (2003)
- Honderlick P, "Uncomplicated urinary tract infections, what about fosfomycin and nitrofurantoin in 2006?", Pathol Biol (Paris), 54, pp.462~466 (2006)
- Hara T, "Antibacterial activities of fosfomycin against several fresh clinical isolates--comparison of the test methods for antibacterial activity", Jpn J Antibiot, 55, pp.844~854 (2002)
- 서미란, "Susceptibility of Escherichia coli from Community-Acquired Urinary Tract Infection to Fosfomycin, Nitrofurantoin, and Temocillin in Korea", Journal of Korean Medical Science, 29(8), pp.1178~1181 (2014), 대한의학회
- Cho YH, "Antimicrobial susceptibilities of extended-spectrum betalactamase-producing Escherichia coli and Klebsiella pneumoniae in health care-associated urinary tract infection:focus on susceptibility to fosfomycin", Int Urol Nephrol, 47, pp.1059~1066 (2015)
- Lee SY, "Prevalence of acquired fosfomycin resistance among extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae clinical isolates in Korea and IS26-composite transposon surrounding fosA3", J Antimicrob Chemother, 67, pp.2843~2847 (2012)